Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma
- PMID: 31372783
- DOI: 10.1007/s00330-019-06351-0
Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma
Abstract
Objective: To determine the diagnostic accuracy and predictive value of gadoxetic acid liver MRI (Gd-EOB-DTPA MRI) alone or in combination with diffusion-weighted imaging (DWI) as a second-line tool for detecting early hepatocellular carcinoma (HCC) recurrence in cirrhotic patients with previous HCC treated with resection or ablation.
Methods: Between 2014 and 2017, we prospectively included 34 cirrhotic patients with complete response to resection and/or ablation of early HCC in whom a new focal lesion enhancing in the arterial phase without washout was detected during follow-up with EC-MRI. After signing the informed consent, all patients underwent DWI and Gd-EOB-DTPA MRI; two readers analyzed signal intensities on each phase of dynamic study and on DWI. The final diagnosis was established by histology or follow-up EC-MRI. We used cross-tabulation to calculate indices of diagnostic accuracy.
Results: We evaluated 34 patients (7 women; 73.5% with hepatitis C virus) with a total of 53 new arterial-phase-enhancing foci (median size, 10 [IQR 9-14] mm). The final diagnosis, reached by histopathology in 15 (35.7%) lesions and EC-MR follow-up in 27 (64.3%), was HCC in 42 (79.2%) and benign conditions in 11 (21.8%). Hepatobiliary-phase hypointensity on Gd-EOB-DTPA MRI plus hyperintensity on DWI yielded 54.8% sensitivity, 90.9% specificity, 95.8% positive predictive value, and 34.5% negative predictive value for diagnosing HCC recurrence.
Conclusion: Among potential indices, combining hypointensity on hepatobiliary-phase Gd-EOB-DTPA MRI and hyperintensity on DWI has the highest specificity and positive predictive value to optimally detect HCC recurrence prior to confident diagnosis by conventional imaging criteria on EC-MRI in cirrhotic liver.
Key points: • In patients at risk of HCC recurrence, the use of gadoxetic acid liver MRI and DWI may improve the differentiation of unspecific new arterial-enhancing foci from early hypervascular HCC recurrence in patients with non-conclusive findings on extracellular liver MRI. • Combined findings on hepatobiliary-phase gadoxetic acid-enhanced liver MRI and DWI had high specificity (90.9%) and positive predictive value (95.8%) for detecting early hypervascular HCC recurrence, but limited sensitivity. • Combining hepatobiliary-phase hypointensity on gadoxetic acid MRI and hyperintensity on diffusion-weighted imaging allows early diagnosis of hypervascular hepatocellular carcinoma and may help select patients for salvage therapy.
Keywords: Cirrhosis; Gadoxetic acid; Hepatocellular carcinoma; Magnetic resonance imaging.
Similar articles
-
Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study.J Magn Reson Imaging. 2020 Jan;51(1):70-80. doi: 10.1002/jmri.26768. Epub 2019 May 6. J Magn Reson Imaging. 2020. PMID: 31062483
-
Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease.Acta Radiol. 2015 May;56(5):526-35. doi: 10.1177/0284185114534652. Epub 2014 May 16. Acta Radiol. 2015. PMID: 24838304
-
Combined Application of Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging (MRI) and Diffusion-Weighted Imaging (DWI) in the Diagnosis of Chronic Liver Disease-Induced Hepatocellular Carcinoma: A Meta-Analysis.PLoS One. 2015 Dec 2;10(12):e0144247. doi: 10.1371/journal.pone.0144247. eCollection 2015. PLoS One. 2015. PMID: 26629904 Free PMC article.
-
Focal lesions in the cirrhotic liver: their pivotal role in gadoxetic acid-enhanced MRI and recognition by the Western guidelines.Dig Dis. 2014;32(6):696-704. doi: 10.1159/000368002. Epub 2014 Oct 29. Dig Dis. 2014. PMID: 25376286 Review.
-
Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging.Eur Radiol. 2020 Jan;30(1):370-382. doi: 10.1007/s00330-019-06369-4. Epub 2019 Aug 5. Eur Radiol. 2020. PMID: 31385048 Free PMC article.
Cited by
-
Advances in application of novel magnetic resonance imaging technologies in liver disease diagnosis.World J Gastroenterol. 2023 Jul 28;29(28):4384-4396. doi: 10.3748/wjg.v29.i28.4384. World J Gastroenterol. 2023. PMID: 37576700 Free PMC article. Review.
-
The Value of Contrast-Enhanced Magnetic Resonance Imaging Enhancement in the Differential Diagnosis of Hepatocellular Carcinoma and Combined Hepatocellular Cholangiocarinoma.J Oncol. 2022 Sep 15;2022:4691172. doi: 10.1155/2022/4691172. eCollection 2022. J Oncol. 2022. PMID: 36157231 Free PMC article.
-
Diagnostic performance of MRI for residual or recurrent hepatocellular carcinoma after locoregional treatment according to contrast agent type: a systematic review and meta‑analysis.Abdom Radiol (NY). 2024 Feb;49(2):471-483. doi: 10.1007/s00261-023-04143-1. Epub 2024 Jan 10. Abdom Radiol (NY). 2024. PMID: 38200213
-
US LI-RADS in surveillance for recurrent hepatocellular carcinoma after curative treatment.Eur Radiol. 2023 Dec;33(12):9357-9367. doi: 10.1007/s00330-023-09903-7. Epub 2023 Jul 18. Eur Radiol. 2023. PMID: 37460801
-
Prediction of early recurrence of hepatocellular carcinoma after resection based on Gd-EOB-DTPA enhanced magnetic resonance imaging: a preliminary study.J Gastrointest Oncol. 2022 Apr;13(2):792-801. doi: 10.21037/jgo-22-224. J Gastrointest Oncol. 2022. PMID: 35557582 Free PMC article.
References
-
- Poon RT, Fan ST, Lo CM, Liu CL, Wong J (2002) Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function. Ann Surg 235:373–382 - DOI
-
- Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S (2015) Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 261:947–955 - DOI
-
- Sala M, Llovet JM, Vilana R et al (2004) Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 40:1352–1360 - DOI
-
- European Association for the Study of the Liver (2018) EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 69:182–236 - DOI
-
- Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750 - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical